AI Company GEDiCube and Renovaro Biosciences Sign Definitive Agreement to Combine
02 oct. 2023 09h25 HE
|
Renovaro Biosciences Inc.
Message from Renovaro Biosciences CEO, The Hon. Mark Dybul, MD LOS ANGELES, Oct. 02, 2023 (GLOBE NEWSWIRE) -- Renovaro Biosciences Inc. (Nasdaq: RENB) Dear Shareholders, I am writing to provide...
Renovaro Biosciences and AI Health Company GEDi Cube Sign Definitive Agreement to Combine
29 sept. 2023 09h15 HE
|
Renovaro Biosciences Inc.
The combined company aims to accelerate precision, personalized medicine for longevity powered by mutually reinforcing AI and biotechnology platforms for early diagnosis, better targeted treatments,...
Renovaro BioSciences Welcomes GEDiCube Announcement of New Joint Effort
30 août 2023 09h15 HE
|
Renovaro Biosciences Inc.
LOS ANGELES, Aug. 30, 2023 (GLOBE NEWSWIRE) -- (NASDAQ: RENB). Renovaro BioSciences congratulates GEDiCube on their joint effort to work to accelerate early diagnosis of cancer in clinical trials. ...
Renovaro BioSciences Congratulates GEDi Cube on Appointment of its Chief Medical Officer
21 août 2023 09h15 HE
|
Renovaro Biosciences Inc.
LOS ANGELES, Aug. 21, 2023 (GLOBE NEWSWIRE) -- (NASDAQ: RENB). Renovaro BioSciences congratulates GEDi Cube on its appointment of Dr. Lester Russell as Chief Medical Officer. For more information:...
AI Company GEDi Cube and Renovaro Biosciences Announce a Binding, Exclusive Letter of Intent to Merge, Accelerating Fight Against Cancer
09 août 2023 09h00 HE
|
Renovaro Biosciences Inc.
Cutting-edge AI/machine learning technology with validation in humans for early diagnosis of lung cancer In silico detection for 12 additional cancers, including pancreaticMore than 2,600 proprietary...
Enochian BioSciences Inc. Announces Adjournment of 2023 Annual Stockholder Meeting
23 juin 2023 17h00 HE
|
Enochian BioSciences, Inc.
LOS ANGELES, June 23, 2023 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB). Enochian BioSciences Inc., a company developing gene-modified cell immunotherapies for cancer and infectious diseases, wishes to advise...
Enochian BioSciences Announces that its Cancer Platform Remains on Track for Trials in Humans Following FDA Review
08 juin 2023 08h45 HE
|
Enochian BioSciences, Inc.
LOS ANGELES, June 08, 2023 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB). Enochian BioSciences Inc. (the Company) announces that it remains confident in submitting an Investigational New Drug Application...
Enochian BioSciences’ CEO Letter to Shareholders
03 avr. 2023 09h00 HE
|
Enochian BioSciences, Inc.
LOS ANGELES, April 03, 2023 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB) -- Accelerated Pre-Investigational New Drug (Pre-IND) submission to the US Food and Drug Administration (FDA) for potential cancer...
Enochian BioSciences Announces a Scientific Presentation of Proof-of-Concept Studies for a Potential Therapy for Cancers with a Poor Life Expectancy by a Leading Researcher
29 mars 2023 09h00 HE
|
Enochian BioSciences, Inc.
LOS ANGELES, March 29, 2023 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB). Enochian BioSciences Inc. (the “Company”) announces that Dr. Anahid Jewett, a renowned cancer researcher in the field of immunotherapy...
Enochian BioSciences Achieves Full Compliance with NASDAQ Filing Requirements
13 mars 2023 08h30 HE
|
Enochian BioSciences, Inc.
LOS ANGELES, March 13, 2023 (GLOBE NEWSWIRE) -- (NASDAQ: ENOB). Enochian BioSciences Inc. (the Company) announced that it has achieved full compliance with NASDAQ filing requirements. The Annual...